Haploidentical NK-cell Infusion in Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Leukemia cells can be killed by natural killer (NK) from HLA-I mismatched donor. The proposed
study plans to realize an adoptive anti-leukaemic immunotherapy by infusion of HLA-I
mismatched NK cells to treat poor prognosis acute myeloid leukemia patients. NK cells will be
selected from HLA mismatch familial donor peripheral mononuclear cells by purification
protocol. Before NK-infusion, patients received immunosuppressive chemotherapy.